Clinical manifestations of post-COVID-19 syndrome
DOI: 10.32364/2587-6821-2022-6-11-612-617
N.S. Asfandiyarova, E.V. Filippov, V.G. Demikhov, O.V. Dashkevich, A.G. Yakubovskaya, K.A. Moseychuk, N.S. Zhuravleva, S.A. Kulikov
Ryazan State Medical University, Ryazan, Russian Federation
Aim: to assess the prevalence of various clinical manifestations in COVID-19 survivors, depending on the time interval after the disease, clinical severity, and the presence of polymorbidity.
Patients and Methods: the study included 253 patients (187 females and 66 males), 18–85 years old, who survived COVID-19. The patients were split into two groups based on the disease severity during the acute phase: group 1 consisted of patients with mild COVID-19 illness (n=133); group 2 consisted of patients with moderate and severe COVID-19 illness (n=120). In addition, patients of each of the groups were divided into two subgroups, depending on the time elapsed from the acute phase of COVID-19 illness: in subgroups A the health assessment of patients was performed within 3 months (12 weeks) after the acute phase of the diseases and in subgroups B — 3 months (12 weeks) after the disease, i.e. the time interval ranged from 3 months to one year after COVID-19 illness. A multi-stage phone interview of the patients was used to reveal the presence of symptoms. Also, outpatient medical records of those patients who addressed therapists or narrow spe cialists, were reviewed.
Results: symptoms were revealed both in patients of subgroup 1A (45/52 (86.5%)) and subgroup 2А (42/45 (93.3%)), or, in other words, the symptoms were absent in 7 (13.5%) and 3 (6.7%) patients, respectively. Three months after COVID-19 illness, the symptoms were absent in 34 (42%) patients of subgroup 1B and in 13 (17.3%) patients of subgroup 2B (p<0.001), while at least one symptom persisted in 47/81 (58%) patients of subgroup 1B and 62/75 (82%) patients of subgroup 2B. In both patient groups the most common symptoms comprised fatigue, shortness of breath, and cough. In group 2 patients central nervous and cardiovascular system consequences and arthralgia were frequently reported. The prevalence of comorbidities was higher in group 2 patients than that in group 1 patients, and the difference was statistically significant (p < 0.01).
Conclusions: the development of post-COVID-19 syndrome does not depend on the illness severity during the acute phase, and it may occur both in mild and moderate or severe cases. However, in the latter category the patients will have more symptoms. In patients recovered from COVID-19, most of the disease sequela were revealed in central nervous, bronchopulmonary, and cardiovascular systems. Comorbidities are associated with the severity of the novel coronavirus disease during the acute phase. COVID-19 survivors need follow-up care during the first three months after the acute phase and in the later period which should be provided by multidisciplinary team of specialists for achieving complete recovery of the patients’ health and improving the quality of life.
Keywords: coronavirus infection, COVID-19, post-COVID-19 syndrome, comorbidities, central nervous system disorders, bronchopulmonary system disorders, cardiovascular system disorders.
For citation: Asfandiyarova N.S., Filippov E.V., Demikhov V.G. et al. Clinical manifestations of post-COVID-19 syndrome. Russian Medical Inquiry. 2022;6(11):612–617 (in Russ.). DOI: 10.32364/2587-6821-2022-6-11-612-617.
About the authors:
Nailya S. Asfandiyarova — Dr. Sc. (Med.), associate professor of the Department of Outpatient Therapy, Preventive Medicine and General Medical Practice, Ryazan State Medical University, 9, Vysokovoltnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-2025-8119.
Evgeniy V. Filippov — Dr. Sc. (Med.), Head of the Department of Outpatient Therapy, Preventive Medicine and General
Medical Practice, Ryazan State Medical University; 9, Vysokovoltnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-7688-7176.
Valeriy G. Demikhov — Dr. Sc. (Med.), Professor, Director of the Research and Clinical Center of Hematology, Oncology and Immunology, Ryazan State Medical University; 9, Vysokovoltnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-6120-4678.
Olga V. Dashkevich — C. Sc. (Med.), associate professor of the Department of Outpatient Therapy, Preventive Medicine and General Medical Practice, Ryazan State Medical University; 9, Vysokovoltnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-6383-5078.
Alina G. Yakubovskaya — C. Sc. (Med.), associate professor of the Department of Outpatient Therapy, Preventive Medicine and General Medical Practice, Ryazan State Medical University; 9, Vysokovoltnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-6994-1947.
Kseniya A. Moseychuk — C. Sc. (Med.), associate professor of the Department of Outpatient Therapy, Preventive Medicine and General Medical Practice, Ryazan State Medical University; 9, Vysokovoltnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-4444-2439.
Nataliya S. Zhuravleva — assistant of the Department of Outpatient Therapy, Preventive Medicine and General Medical Practice, Ryazan State Medical University; 9, Vysokovoltnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-9478-3629.
Sergey A. Kulikov — assistant of Prof. V.Ya. Garmash Department of Intermediate Level Therapy, Preventive Medicine and General Medical Practice, Ryazan State Medical University; 9, Vysokovoltnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0001-8264-6689. Contact information: Nailya S. Asfandiyarova, e-mail: n.asfandiyarova2010@yandex.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 06.12.2021.
Revised 29.12.2021.
Accepted 28.01.2022.
2. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. (Electronic resource.) URL: https://www.nice.org.uk/guidance/ng188 (access date: 20.11.2021).
3. Nalbandian A., Sehgal K., Gupta A. et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. DOI: 10.1038/s41591-021-01283-z.
4. Amenta E.M., Spallone A., Rodriguez-Barradas M.C. et al. Post-acute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7(12):ofaa509. DOI: 10.1093/ofid/ofaa509.
5. Arnold D.T., Hamilton F.W., Milne A. et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76:399–401. DOI: 10.1136/thoraxjnl-2020-216086.
6. Chopra V., Flanders S.A., O'Malley M. et al. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Ann Intern Med. 2021;174(4):576–578. DOI: 10.7326/M20-5661.
7. Halpin S.J., McIvor C., Whyatt G. et al Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021;93(2):1013–1022. DOI: 10.1002/jmv.26368.
8. Moreno-Pérez O., Merino E., Leon-Ramirez J-M. et al. Post-acute COVID-19 Syndrome incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82(3):378–383. DOI: 10.1016/j.jinf.2021.01.004.
9. Willi S., Lüthold R., Hunt A. et al. COVID-19 sequelae in adults aged less than 50 years: a systematic review. Travel Med Infect Dis. 2021;40:101995. DOI: 10.1016/j.tmaid.2021.101995.
10. Carfì A., Bernabei R., Landi F.; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603–605. DOI: 10.1001/jama.2020.12603.
11. Carvalho-Schneider C., Laurent E., Lemaignen A. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27(2):258–263. DOI: 10.1016/j.cmi.2020.09.052.
12. Pavli A., Theodoridou M., Maltezou H.C. Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52(6):575–581. DOI: 10.1016/j.arcmed.2021.03.010.
13. Козлов И.А., Тюрин И.Н. Сердечно-сосудистые осложнения COVID-19. Вестник анестезиологии и реаниматологии. 2020;17(4):14–22. DOI: 10.21292/2078-5658-2020-17-4-14-22. [Kozlov I.А., Tyurin I.N. Cardiovascular complications of COVID-19. Messenger of Anesthesiology and Resuscitation. 2020;17(4):14–22 (in Russ.)]. DOI: 10.21292/2078-5658-2020-17-4-14-22.
14. Смирнова Е.А., Седых Е.В. Острая декомпенсация сердечной недостаточности: актуальные вопросы эпидемиологии, диагностики, терапии. Наука молодых (Eruditio Juvenium). 2021;9(2):289–300. DOI: 10.23888/HMJ202192289-300. [Smirnova E.A., Sedykh E.V. Acute decompensation of heart failure: current issues of epidemiology, diagnostics, therapy. Science of the young (Eruditio Juvenium). 2021;9(2):289–300 (in Russ.)]. DOI: 10.23888/HMJ202192289-300.
15. Aghagoli G., Gallo Marin B., Soliman L.B., Sellke F.W. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review. J Card Surg. 2020;35(6):1302–1305. DOI: 10.1111/jocs.14538.
16. Chen C., Zhou Y., Wang D.W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;45(3):230–232. DOI: 10.1007/s00059-020-04909-z.
17. Kochi A.N., Tagliari A.P., Forleo G.B. et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31(5):1003–1008. DOI: 10.1111/jce.14479.
18. Maiti T., Essam L., Orsolini L. et al. COVID-19-индуцированные психозы: новые вызовы для начинающих карьеру психиатров. Российский медико-биологический вестник им. академика И.П. Павлова. 2021;29(2):325–331. DOI: 10.17816/PAVLOVJ72035. [Maiti T., Essam L., Orsolini L. et al. COVID-19-induced psychoses: new challenges for aspiring psychiatric careers. IP Pavlov Russian Medical Biological Herald. 2021;29(2):325–331 (in Russ.)]. DOI: 10.17816/PAVLOVJ72035.
19. Li G., Yang Y., Gao D. et al. Is liver involvement overestimated in COVID-19 patients? A meta-analysis. Int J Med Sci. 2021;18(5):1285–1296. DOI: 10.7150/ijms.51174.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать